trending Market Intelligence /marketintelligence/en/news-insights/trending/QjGCij1vOHxobuj37W3uUg2 content esgSubNav
In This List

AstraZeneca exec to replace GSK's outgoing global pharmaceuticals president

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals

Blog

The Future of Risk Management Digitization in Credit Risk Management

Blog

Climate Credit Analytics: Diving into the model


AstraZeneca exec to replace GSK's outgoing global pharmaceuticals president

GlaxoSmithKline PLC appointed Luke Miels president of global pharmaceuticals.

Miels, whose start date was not given, is currently AstraZeneca PLC's executive vice president for Europe. Miels will report to GSK CEO Designate Emma Walmsley, who will become permanent CEO in April.

Miels replaces Abbas Hussain, who will leave GlaxoSmithKline later in 2017. Hussain, who joined GSK in 2008, is also a director at HIV-focused ViiV Healthcare.

Before joining AstraZeneca, Miels served Roche as regional vice president Asia-Pacific for the pharmaceuticals division.